Hematological and dermatological adverse events during hepatitis C treatment with peg-interferon and ribavirin
Main Article Content
Resumo
Objective: To evaluate frequency and impact of adverse events, mainly the hematological and dermatological ones, on sustained virological response, and compliance to hepatitis C treatment. Methods: Patients were treated according to the guidelines of the Brazilian Ministry of Health. Variables associated with hematological and dermatological adverse events were: age, gender, stage of fibrosis, type of Pegylated interferon, dose reductions, temporary discontinuation and early interruption of treatment. Results: Two hundred and twenty two patients were studied (58% females; age 49±11 years). Dose reductions, temporary interruptions, and early discontinuations were observed in 21%, 8% and 9.5% of patients, respectively. The main adverse events were hematological (anemia, neutropenia and thrombocytopenia) and dermatological (pruritus and alopecia). Anemia (Hemoglobin <10g/dL) was associated with female gender (p<0.001), advanced fibrosis (p=0.047) and dose reductions (p<0.001); neutropenia with advanced fibrosis (p=0.003) and temporary discontinuation (p=0.002); thrombocytopenia with advanced fibrosis (p<0.001) and pegylated interferon α2a (p=0.05). Pruritus and alopecia were associated to female gender (p=0.008 and p=0.02) and treatment interruption (p=0.029 and p=0.02). Conclusion: Hematological and dermatological adverse events are frequent in hepatitis C patients treated with pegylated interferon and ribavirin. However, despite frequent dose reductions and interruptions, these adverse events did not affect the sustained virological response.
Article Details
Declaração de Direito Autoral
Eu (nome do autor responsável) _______________________________________________ declaro que o presente artigo intitulado ___________________________________é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade. Declaro, ainda, que uma vez publicado na revista Revista da Sociedade Brasileira de Clinica Médica, editada pela Sociedade Brasileira de Clínica Médica, o mesmo jamais será submetido por um dos demais co-autores a qualquer outro meio de divulgação científica impressa ou eletrônica.
Por meio deste instrumento, em meu nome e dos demais co-autores, cedo os direitos autorais do referido artigo à Revista da Sociedade Brasileira de Clinica Médica, e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (n 9610 19 de fevereiro de 1998) que altera, atualiza e consolida a legislação sobre direitos autorais e dá outras providências. Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l9610.htm
_________________________ |
___________________ |
Local, data |
Assinatura |
SOCIEDADE BRASILEIRA DE CLÍNICA MÉDICA
CNPJ/MF 062.279.617/0001-45
Rua Botucatu, nº 572, cj. 112, São Paulo, SP
Download da Declaração de Direito Autoral.